on Relief Therapeutics Holding SA (ETR:RLF)
Relief Therapeutics Shareholders Approve Merger with NeuroX
Relief Therapeutics Holding SA has received shareholder approval for its business combination with NeuroX Group SA. This merger aims to create a public digital neurotherapeutics company. Expected to finalize in December 2025, the business will be renamed MindMaze Therapeutics Holding SA. Key leadership roles will be filled by current NeuroX executives Alexandre Capet and Frédéric Condolo.
Shareholders authorized a capital increase through the issuance of 140 million new shares in exchange for NeuroX shares. The new board members include Walid Hanna, Olaf Blanke, Michael Stuenkel, and Martin Reiss.
A joint press conference is scheduled for November 25, 2025, to discuss strategic plans. The transaction's completion is subject to regulatory approvals, including the new shares' listing on the SIX Swiss Exchange.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Relief Therapeutics Holding SA news